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Objective: Approval by the United States Food and Drug Administration of endoluminal repair of abdominal aortic
aneurysm (AAA) with the AneuRx stent graft was based on the outcome of a multicenter trial in which patients met strict
inclusion and exclusion criteria. Since widespread use of the commercially available graft, little information is available as
to whether indications and outcomes have evolved. We examined this important issue at our institution.
Methods: Data concerning indications, repair, and follow-up for all patients undergoing endoluminal repair of AAA was
prospectively entered into a patient registry. Group 1 comprised consecutive patients enrolled in the AneuRx Phase III
clinical trial between November 1998 and September 2000. Group 2 consisted of consecutive patients who underwent
implantation of the commercially available AneuRx graft between May 1999 and June 2001.
Results: Group 1 included 42 patients (mean age, 72 years), and group 2 included 54 patients (mean age, 73 years).
Patient demographics and risk factors were similar between the two groups. Maximum aortic aneurysm diameter was
significantly greater (P .021) in group 1 (55 mm 10.9 [SD] mm) compared with group 2 (52 15.6 mm). Maximum
infrarenal aortic neck length was significantly longer (P  .022) in group 1 (30  11.7 mm) than in group 2 (23  12.0
mm). Maximum left common iliac artery diameter in group 1 (13.0  3.2 mm) was significantly smaller (P  .032) than
that in group 2 (14  6.5 mm). During follow-up, no differences were observed for number of endoleaks, subsequent
interventions, or graft explantation between the two groups.
Conclusions: In group 2 patients AAAs were significantly smaller, infrarenal aortic neck length was shorter, and left
common iliac arteries were larger. Common iliac artery ectasia and aneurysmal disease has become another indication for
use of the AneuRx commercial graft at our institution, with no significant differences in intermediate outcome. Given the
possibility for evolving indications compared with trial inclusion and exclusion criteria, institutions that use the AneuRx
commercial graft should prospectively monitor outcomes for quality assurance. (J Vasc Surg 2003;37:739-43.)
On September 28, 1999, the United States Food and
Drug Administration (FDA) granted market approval for
the AneuRx stent graft for treatment of infrarenal abdom-
inal aortic aneurysm (AAA). The approval, guided by the
FDA advisory panel in June 1999, was based on 1-year
results of the US Phase II clinical trial that compared use of
the AneuRx stent graft with open surgical aneurysm re-
pair.1,2 Phase II began in April 1997 and was carried out at
13 qualified clinical sites throughout the United States,
including our institution. For enrollment in the trial, 424
patients receiving the AneuRx stent graft met strict inclu-
sion and exclusion criteria.2 Criteria that addressed impor-
tant anatomic information, eg, aneurysm size and infrarenal
aortic neck length, and patient medical history were de-
signed to make valid comparisons with open repair and to
maximize safety as applied to the design of the stent graft.
Since FDA approval, an expected increase in use of the
AneuRx stent graft has been observed. As of June 2000,
more than 9000 patients have received the device.2 Given
the widespread availability of the AneuRx commercial graft
to other institutions and specialties, the question arises as to
whether new indications for the graft will evolve and, more
important, if so, will outcomes remain similar to those
described from the multicenter trial. We compared our
experience as a Phase III AneuRx trial site with subsequent
use of the AneuRx commercial graft to address this impor-
tant question.
METHODS
Beginning with the Phase III clinical trial for the An-
euRx stent graft, data on indications, repair, and follow-up
for all patients undergoing endoluminal repair of AAA were
prospectively entered into a computer database (Access;
Microsoft, Redmond, Wash). Preoperative evaluation, An-
euRx stent graft implantation, and postoperative follow-up
was performed by vascular surgeons who are faculty in the
Division of Vascular Surgery at Southern Illinois University
School of Medicine in Springfield, Ill. The bifurcated,
self-expanding AneuRx stent graft (Medtronics/AneuRx,
Sunnyvale, Calif) was used in all patients. All patients
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underwent preoperative arteriography and contrast
medium–enhanced helical computed tomography (CT).
All AneuRx stent graft procedures were performed in the
cardiac catheterization laboratory at Memorial Medical
Center, Springfield, Ill, with most patients under local
anesthesia combined with intravenous sedation.3 Group 1
consisted of consecutive patients in whom the AneuRx
stent graft was implanted as part of the Phase III trial
between November 1998 and September 2000. Group 2
consisted of consecutive patients in whom the commer-
cially available AneuRx stent graft was implanted between
May 1999 and June 2001. The institutional review board
approved the AneuRx Phase III trial, and patient partici-
pants gave informed consent.
Patient demographics, risk factors, adjuvant interven-
tions, and complications were prospectively recorded in a
vascular patient registry (Vascubase, Seattle, Wash). Peri-
operative risk factors were designated as past or present
tobacco use; diabetes mellitus requiring treatment with
insulin or an oral medication; hypertension requiring anti-
hypertensive medication; hyperlipidemia requiring treat-
ment with a lipid-lowering agent, or fasting cholesterol
concentration greater than 220 mg/dL; renal insufficiency,
with baseline creatinine concentration greater than 2.0
mg/dL; documented history of coronary artery disease,
cerebrovascular disease, or symptomatic lower extremity
atherosclerotic occlusive disease; and chronic obstructive
pulmonary disease requiring treatment with medication.
Potential adjuvant interventions included preoperative in-
ternal iliac artery embolization, perioperative conversion to
open surgical repair, endovascular treatment of endoleak,
and graft explantation during follow-up. Complications
were reported as local vascular, local nonvascular, or remote
systemic, as recommended by the Ad Hoc Committee for
Standardized Reporting Practices in Vascular Surgery of
The Society for Vascular Surgery/International Society for
Cardiovascular Surgery.4,5
Inclusion and exclusion criteria relating to arterial anat-
omy for the AneuRx Phase III trial were identical to those
for Phase II (Table I).2 As cited in the inclusion criteria, the
maximum common iliac artery diameter used to safely
deploy the stent graft at our institution was 24 mm. The
AneuRx stent graft system was oversized 10% to 20% to
ensure adequate arterial seal. The device was delivered
through a retrograde endoluminal approach via bilateral
open common femoral artery exposure. Additional modu-
lar stent graft components were used as required by ana-
tomic variation. The “bell bottom” technique and “tele-
scoping” techniques were also used to address anatomic
variation in the iliac arteries.6,7 Follow-up imaging for the
Phase III trial has been reported.2 Patients receiving the
commercial AneuRx stent graft underwent plain abdominal
radiography and CT at 1, 6, and 12 months and annually
thereafter. The protocol for CT, previously outlined in
detail,8 was identical for patients participating in the Phase
III trial and those receiving the commercial AneuRx stent
graft. Endoleaks were designated according to the standard
classification of types I to IV.9 Patients with endoleaks
detected at 1-month follow-up underwent CT at 3 months.
If endoleak was present at 3-month follow-up, arteriogra-
phy and, if possible, endovascular treatment with coil em-
bolization or additional stent graft was performed.
For purposes of statistical comparison, applicable re-
sults are expressed as mean or median, with minimum and
maximum values and standard deviation. Confidence inter-
vals (95%) are provided for pertinent percents. Differences
between groups were examined with the Wilcoxon rank
sum test (version 9.0; SPSS, Chicago, Ill). P  .05 was
considered statistically significant.
RESULTS
Forty-two patients enrolled in the AneuRx Phase III
trial composed group 1, and 54 patients with a commercial
AneuRx stent graft composed group 2. Mean age in group
1 was 72 years, and in group 2 was 73 years. Men accounted
for 83% of patients in group 1 and 93% of patients in group
2. Patient demographics and risk factors between groups
are compared in Table II. No significant differences were
observed, with the exception of median follow-up (24
months in group 1, 12 months in group 2; P  .0005).
Significant differences were noted between group 1 and
group 2 when comparing preoperative arterial anatomy and
endovascular interventions. Maximum aortic diameter in
group 1 (median, 55 mm; range, 40-80 mm; SD  10.9
mm) was significantly larger (P  .021) than that in group
2 (median, 52 mm; range, 23-120 mm; SD  15.6 mm).
Table I. Inclusion and exclusion criteria related to arterial anatomy for AneuRx Phase III clinical trial
Inclusion criteria
Aneurysm 5 cm in diameter
Aneurysm 4-5 cm in diameter and has increased in size by 0.5 cm in last 6 months
Aneurysm twice the diameter of normal infrarenal aorta
Aneurysm is sacular
Minimum neck length 1 cm nonaneurysmal aorta immediately inferior to most inferior major renal artery
Nonaneurysmal proximal aortic neck diameter 18-25 mm
Patient vascular dimensions (eg, aortic and iliac diameters, length from renal arteries to iliac bifurcation and hypogastric arteries)
must be in range that can be safely treated with available stent graft
Exclusion criteria
Thoracic, suprarenal, iliofemoral, or inflammatory aneurysm
Ruptured or leaking aneurysm
Morbid obesity or other clinical condition that severely inhibits radiographic visualization of aorta
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Maximum infrarenal aortic neck length was significantly
longer (P  .022) in group 1 (median, 30 mm; range,
10-50 mm; SD  11.8 mm) compared with group 2
(median, 26 mm; range, 10-76 mm; SD  12.3 mm).
Maximum left common iliac artery diameter in group 1
(median, 13.0 mm; range, 9-20 mm; SD  3.2 mm) was
significantly smaller (P  0.032) than that in group 2
(median, 14.0 mm; range, 10-38 mm; SD 6.1 mm). In 2
patients (5%) in group 1, one or both common iliac arteries
were 30 mm or larger, and in 1 of these patients (2%) AAA
was  5 cm. In contrast, in 12 patients (22%) in group 2,
one or both common iliac arteries were 30 mm or larger,
and in 9 patients (17%) AAA was  5 cm (P  .034).
Preoperative arterial anatomic variation and endovascular
interventions between the two groups for all parameters are
compared in Table III. When examining deployment of the
AneuRx stent graft in the two groups, no significant differ-
ences were observed in perioperative treatment. Each of
these intraoperative treatments in the two groups is com-
pared in Table IV. Follow-up revealed a similar number of
endoleaks in the two groups at different times, and no
difference in number of subsequent endoleak interven-
tions. Number of endoleaks and interventions are com-
pared between groups in Table V. Morbidity developed in
2 patients (4.7%) in group 1 and in 3 patients (5.5%) in
group 2 (P  .772). Late external iliac artery stenosis
developed in 1 patient in group 1, and 1 patient had
perioperative myocardial infarction. Two late iliac graft
thromboses and 1 early groin wound infection occurred in
group 2. One-year survival for group 1 was 93%, and for
group 2 was 98% (P  0.628). All of these patients died of
causes unrelated to the endovascular stent graft.
DISCUSSION
Implantation of the AneuRx stent graft in all phases of
the US clinical trial was effective treatment for prevention
of AAA rupture during short and intermediate follow-up.2
Nineteen medical centers, including our institution, partic-
ipated in the trials, in which the primary investigators were
chosen because of large experience with endovascular pro-
cedures and catheter and guide wire skills. One-year fol-
low-up results from the Phase II trial led to FDA approval
of the device in September 1999, and since then the graft
has been deployed in thousands of patients in many other
institutions by physicians with, more than likely, varying
levels of experience. Currently, training for physicians and
surgeons who desire to become competent in AneuRx stent
graft placement involves participation in a didactic course
sponsored by Medtronics, Inc, and then performing a
minimum number of procedures, usually four or five, at the
trainee’s institution with the guidance of a proctor certified
by the company. Involvement of multiple specialties partic-
ipating in use of the commercial AneuRx stent graft, in the
absence of strict inclusion and exclusion criteria from an
FDA-regulated clinical trial, conveys the important ques-
tion of whether indications for AAA repair may evolve and
broaden while maintaining similar outcomes.
From our institution, the most prominent difference
between patients enrolled in the Phase III AneuRx clinical
trial and those receiving a commercially available graft was
the significant decrease in aneurysm size. Patients enrolled
in the AneuRx Phase III trial had a median maximum AAA
diameter of 55 mm, compared with 52 mm in patients
receiving the commercial AneuRx graft. Median infrarenal
aortic neck length was significantly longer in group 1 (30
mm) compared with group 2 (23 mm). Conversely, pa-
tients with the commercial graft had significantly larger
common iliac arteries on the left, and 12% of these patients
had preoperative internal iliac artery embolization, com-
pared with 2% of patients in Phase III. The downward trend
in size of AAA treated with commercial AneuRx stent graft
occurred because a moderate proportion of patients with
AAA smaller than 5 cm had common iliac artery aneurysms.
Twelve patients who received the commercial graft had
common iliac arteries 30 mm or larger, of which 9 had AAA
smaller than 5 cm. This information provides more clarity
to the significant difference between the two groups in
median diameter of the left common iliac artery of only 1
mm.
These data show evolving flexibility of the AneuRx
stent graft at our institution for treatment of more complex
AAAs, particularly those with concomitant iliac artery ecta-
sia or aneurysm disease. Although no strict exclusion crite-
ria addressing maximum common iliac artery diameter was
used in the Phase III trial, evolution of internal iliac artery
embolization was not routine at our institution until near
the end of the trial. In addition, preoperative internal iliac
artery embolization can be used before AneuRx stent graft
deployment to treat common iliac artery aneurysm, a dis-
ease not included in the AneuRx clinical trial.
Despite the large number of commercial AneuRx stent
grafts being placed, few comparisons have been made with
the AneuRx clinical trials. Adelman et al10 expressed con-
cern that since FDA approval indications for repair have
become more relaxed and outcomes worse. They compared
Table II. Comparison of patient demographics and risk
factors between AneuRx Phase III clinical trial (group 1)




(n  54) P
Follow-up (mo; median  SD) 24  11.0 12  11.0 .0005
Age (y; mean  SD) 72  9.0 73  8.9 .78
Male 35 (83) 50 (93) .20
Smoker 22 (52) 29 (54) 1.00
Diabetes 2 (5) 2 (4) 1.00
Hypertension 27 (64) 28 (52) .31
Hypercholesterolemia 11 (26) 14 (26) 1.00
Renal insufficiency 7 (16) 6 (11) .63
Coronary artery disease 35 (83) 42 (77) .67
Cerebrovascular disease 11 (26) 20 (37) .36
Lower extremity atherosclerotic
occlusive disease
5 (12) 6 (11) 1.00
Chronic obstructive pulmonary
disease
13 (31) 16 (30) 1.00
Values in parentheses represent percent.
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similar parameters in 46 patients enrolled in the AneuRx
clinical trial and 84 patients with a commercial AneuRx
stent graft. Thirty percent of patients in the commercial
AneuRx stent graft group had shorter aortic necks (15
mm), compared with no patients in the clinical trial. Al-
though perioperative conversion to open repair declined
from 11% to 2.5%, proximal or distal attachment leak
occurred more often in patients receiving the commercial
AneuRx graft than in those enrolled in the clinical trial
(14.3% vs 4.3%, respectively; P  .14). Overall, postopera-
tive endoleak was noted at follow-up in 24% of patients in
the commercial AneuRx group and 33% of those in the
clinical trial group. At 12-month follow-up at our institu-
tion, 4% of patients with a commercial AneuRx stent graft
had persistent endoleak, versus 12% of patients enrolled in
the Phase III trial. No differences were noted in aortic neck
diameter between the two groups, and no patient required
perioperative conversion to open repair at our institution.
Table III. Comparison of arterial anatomy between AneuRx Phase III clinical trial (group 1) and commercial AneuRx
stent grafts (group 2)
Arterial anatomy
Group 1 (n  42) Group 2 (n  54)
PMedian Range Median Range
Maximum diameter (mm) 55  10.9 40-85 52  15.6 23-120 .021
Neck diameter (mm) 24  3.0 18-30 23  2.4 18-30 .743
Neck length (mm) 30  11.8 10-50 26  12.3 10-76 .023
Right iliac artery diameter (mm) 13.5  5.7 10-36 14.5  7.1 9-42 .343
Left iliac artery diameter (mm) 13.0  3.2 9-20 14.0  6.5 10-38 .032
Common iliac artery aneurysm present
(30 mm)
2 (5) 12 (22) .033
Internal iliac artery embolization 1 (2) 6 (11) .132
Common or external iliac artery
percutaneous transluminal
angioplasty
5 (12) 9 (17) .716
Results expressed as median  SD.
Numbers in parenthesis represent percent.
Table IV. Comparison of perioperative treatment between AneuRx Phase III clinical trial (group 1) and commercial
AneuRx stent grafts (group 2)
Perioperative treatment characteristics
Group 1 (n  42) Group 2 (n  54)
Pn % n %
Aortic extension cuffs 9 21 4 7 .091
Iliac extension cuffs 21 50 34 63 .287
Iliac limb graft “bell bottom” technique 7 17 5 9 .437
Iliac limb graft “telescoping” technique 4 10 6 11 1.000
Local anesthesia 37 88 49 91 .744
Perioperative conversion to open repair 0 0
Length of hospital stay (d)*
Median  SD 2.50  1.58 2.35  1.18 .608
Range 2-9 1-7
Table V. Patients with persistant endoleak and endoleak intervention during follow-up between AneuRx Phase III
clinical trial (group 1) and commercial AneuRx stent grafts (group 2)
Follow-up
Group 1 (n  42) Group 2 (n  54)
Pn % CI n % CI
Number of endoleaks
3 mo 7 16 8-32 6 11 5-23 .625
6 mo 7 16 8-32 4 7 2-19 .203
12 mo 4 10 3-24 2 4 1-14 .399
Endoleak intervention
Coil embolization 4 10 3-24 3 6 1-16 .694
Extension cuff placement 1 2 0-14 0 0-8 .438
Graft explanted 2 5 1-17 0 0-8 .189
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Certainly the inability to reach statistical significance for
certain parameters compared in each group may be a func-
tion of inadequate statistical power in this small study.
Nevertheless, this weakness does not negate the important
differences that were discovered.
Reasons for the paucity of complications in our series
more than likely stem from the authors’ substantial experi-
ence with advanced catheter and guidewire skills, large
experience with placement of the AneuRx stent graft, and
the minimally invasive nature of the procedure. In addition,
similar outcome in patients receiving the commercial An-
euRx stent graft were achieved by still maintaining many of
the original inclusion and exclusion criteria from the Phase
III Trial. As more physicians from different institutions
learn the procedure, the question of whether other indica-
tions may evolve remains important. Although AAA size in
our patients decreased from a median of 55 mm to 52 mm,
concomitant increase in common iliac artery diameter on
the left was observed. Our indications evolved to include
the treatment of common iliac artery aneurysm while ob-
serving similar outcomes compared with the AneuRx Phase
III Trial during intermediate follow-up. Other important
factors, eg, patient age, comorbid conditions, long-term
durability, and “pushing the anatomic envelope” of repair,
are central forces to changing indications for AAA repair.
These forces may be driven more by local institutional
characteristics, eg, physician experience and knowledge,
referral patterns, and geographic area, than by indications
dictated from a national trial. Nevertheless, importance of
the natural history of AAA cannot be overemphasized. The
annual rupture rate for AAA smaller than 4 cm is near zero,
and for AAA 4 to 4.9 cm is 1% per year.11-13 Importance of
the risk-benefit ratio in endoluminal repair of aneurysm
must be weighed heavily in these patients, despite the newly
perceived invasiveness of open surgical repair. Physicians
gaining skill in placement of the AneuRx stent graft should
become well versed in the natural history of AAA disease
and closely follow how indications and outcomes may be
changing over time within their own institution.
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